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ABSTRACT
Tumor necrosis factor α-induced protein 3-interacting protein 1 (TNIP1) is a negative
regulator of inflammatory signaling in several diseases. TNIP1 is also an intrinsically disordered
protein (IDP), which makes it difficult for current drugs to affect it. More research on IDPs could
lead to novel drugs targeting TNIP1, leading to improved therapies for patients with acute and
chronic inflammatory diseases. The main difference between IDPs and the more common
ordered proteins is that IDPs are flexible, a characteristic of TNIP1 which was demonstrated in
this study via protease sensitivity. Ordered proteins are rigid, which means that they only have
one well-defined three-dimensional structure. The flexibility of IDPs allows them to have
multiple conformations that they can switch between quite easily. However, switching between
conformations makes it much harder to solve for the structure of an IDP. Since developing drugs
relies heavily on knowing a protein’s structure, IDPs have not yet been common therapeutic
targets. Several screening approaches for new IDP-targeting drugs are considered here, including
those driven by artificial intelligence. There have been some reports of successful small molecule
screens, but finding a universal technique is still in high demand. Currently, it is thought that
drugs binding to multiple conformations of IDPs may be beneficial over a drug only binding a
single conformation. Since 20-30% of the proteins in our body are IDPs, continued
characterization of IDPs could lead to better drug designing methods, more structural
information about TNIP1, and a better multifaceted approach for treating psoriasis, cancer,
Parkinson’s disease, ischemic vascular diseases, and beyond.
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INTRODUCTION
All of the proteins in our body can be characterized by their structure. The structures of
these proteins are largely due to their unique amino acid sequences. Typically, the amino acid
sequences help the protein fold into a stable, ordered, and specific three-dimensional
conformation. In many cases, these well-defined ordered proteins have biological activity in our
body. However, there are proteins that can have biological activity without a stable threedimensional structure. These proteins are called intrinsically disordered proteins (IDPs), which
are unfolded, flexible, and capable of rapidly changing conformations. IDPs play a major role in
many biological processes and disease states in humans [1]. Reduced function of tumor necrosis
factor α–induced protein 3-interacting protein 1 (TNIP1), an IDP, has been linked to
inflammatory skin diseases [2,3]. Gaining a better understanding of the varying conformations of
TNIP1 could lead to a promising drug target in inflammatory skin disease states. To support this
connection between IDP conformation and drug targets, the distinction between IDPs and
ordered proteins must be made.
While ordered and disordered proteins may seem like two separate binary states, the
amount of disorder in proteins is described as a continuum [4]. For example, there are hybrid
proteins that are described as a mix between ordered and disordered, which is due to intrinsically
disordered protein regions (IDPRs) within their structure. Also, it is important to note that neither
of the extremes on this continuum exist. All proteins have some degree of movement, but they
cannot be completely chaotic either. The structure disorder-continuum is complex, so
distinguishing between ordered proteins and IDPs can be challenging. However, some [5]
theorize that a protein can be considered an IDP when it cannot be described by having a single
three-dimensional conformation, or at least within a series of snapshots. In some instances,
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determining whether a protein fits this IDP definition of “conformational uncertainty” involves
an environmental context, such as an interaction with a partner protein [5].

Human Proteome:
To put IDPs in the context of the human proteome, IDPs were described as proteins that
have more than 30% of disordered residues in their polypeptide chain. Using this quantitative
threshold, over twenty thousand proteins in the human proteome were analyzed and 32% were
characterized as IDPs, 19% characterized as containing IDPRs, and 49% characterized as
ordered proteins [6]. However, there is a misconception that IDPs are uncommon, which may be
due to the fact that only 0.9% of eukaryote proteomes are fully (highly) disordered [7]. Given the
large presence of IDPs in the body, it is important to understand the various functions that they
carry out.

IDP functional diversity:
Unlike typical ordered proteins, IDPs are flexible which allow them to have a multitude
of conformations and therefore a variety of functions. This structure-function relationship is
evident when looking at various disease states in humans [1]. In Parkinson’s disease there is an
IDP called α-Synuclein (α-Syn). The mechanism of α-Syn-related pathology is not well-defined,
but it is theorized that it is involved with neuronal transmission as well as membrane thinning,
curvature, and remodeling. There has also been mounting evidence that associates α-Syn
dysfunction with damage of multiple organelles and α-Syn genetic abnormalities with familial,
early onset Parkinson’s disease [8]. There is an IDP called c-Myc, which acts as a transcription
factor of various genes that regulate many functions involved with cancer. The overexpression of
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c-Myc leads to the proliferation of many human cancers such as, breast cancer, colon cancer, and
cervical cancer [9]. In psoriasis, TNIP1 was found to directly control IL-17A-mediated gene
regulation in keratinocytes [10]. Due to its flexible nature, TNIP1 can also repress intracellular
signaling and transcription by binding to multiple factors such as, RAR, PPAR, and NFκB
[11,12,13]. Loss of TNIP1 leads to increased chemokine recruitment and ultimately
inflammation that is consistent with psoriasis [2]. Gaining a better understanding of the varying
conformations of TNIP1, and other IDPs, could lead to more information about how IDPs can be
targeted in our body. Investigating how IDPs can change their conformation when bound to
partner proteins and in their free state provides a foundation that is necessary for drug design.

IDPs IN A BOUND STATE
Intrinsically disordered regions (IDRs) within IDPs give IDPs their flexibility. This
allows for IDPs to bind to many different proteins and have one protein bind to multiple places
on the same IDP. These mechanisms are referred to as one-to-many binding and many-to-one
binding respectively. One-to-many binding allows for p53, a tumor suppressor IDP, to bind to
over 100 different partners. p53 utilizes its many IDRs that each bind multiple partners, which
enables p53 to bind to all of its different targets. Many-to-one binding allows for 14-3-3, an IDP
[14], to have one protein bind to many of its 200+ IDRs. These interactions are called many-toone binding because many of the IDRs on 14-3-3 are able to bind one identical amino acid
sequence [14]. One-to-many binding and many-to-one binding show how one dysfunctional IDP
can have a large effect on multiple signaling pathways within the body.
Most IDPs become more ordered after they are bound to their target. Unfortunately, there
are some IDPs that maintain their disorder even after binding to their target, which makes
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characterizing their changing conformations difficult [15]. However, this unusual phenomenon
can be predicted using a FuzPred algorithm. The algorithm uses the sequences of over two
thousand complexes to predict whether an IDP will transition from disordered-to-ordered,
disordered-to-disordered, or somewhere between the two ends of the spectrum [16]. Given that
understanding the various conformations of IDPs is imperative for drug design, it is important to
discuss how the IDPs that transition from disordered-to-ordered when binding are able to do so.

Conformation when binding:
The transition of IDPs from unbound to bound (disordered-to-ordered) and bound to
unbound (ordered-to-disordered) can be guided by the electrostatic interactions between the IDP
and the binding site. As shown in p53 fragments, the electrostatic interactions predominate at a
long-range (10-20 Å), which facilitates the IDP folding into a more stable conformation. Once
the IDP is close to the binding site, van der Waals forces predominant, which stabilizes the
ordered conformation of the IDP. When the IDP is becoming unbound and transitioning from
ordered-to-disordered, some order may be retained in the short-term depending on the distance
between the IDP and its receptor. If the rate of unfolding is faster than the rate of unbinding then
the IDP will regain its disorder before the IDP has lost all of its contact points with its receptor.
However, the IDP can briefly maintain its stable bound conformation if the rate of unbinding is
faster than the rate of unfolding [15]. The mechanism by which the IDP actually binds to its
target is affected by a number of factors.
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IDP binding mechanisms:
IDPs can bind to their targets in a few ways, “Several possible binding mechanisms for
coupled folding and binding have been identified: folding of the IDP after association with the
target (“induced fit”), or binding of a prefolded state in the conformational ensemble of the IDP
to the target protein (“conformational selection”), or some combination of these two extremes”
[17]. The actual reactions behind these mechanisms are independent from one another, and
depend on the conformational propensities of both the IDP and the receptor it is targeting [17]. It
is also important to note that becoming ordered when bound does not correlate with an increased
affinity for the receptor. The various intermediate conformations that may be involved with
binding are independent from one IDP to another. In addition, the intermediates that are involved
when an IDP binds to its receptor can depend greatly on the cellular environment that the IDP is
in. IDPs that undergo different conformational changes as a result of the environment or
propensities of its target protein use a binding mode known as a context-dependent. The
environment can also dictate how the IDP changes between its various conformations when it is
unbound [16].

IDPs IN AN UNBOUND STATE
When IDPs are unbound and in their free form, their conformation depends on two major
variables: the IDP’s conformational propensities and the environment. Even in stable
physiological conditions, IDPs can undergo many conformational changes on their own. The
rapid changing between sub-states is likely due to small energy barriers [15]. The small energy
barriers allow for the IDP to change its conformation rapidly on its own, but this also allows for
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the environment to have a notable impact on IDPs. Before analyzing the effects of environmental
factors, the structural properties of IDPs in physiological conditions needs to be discussed first.
Two important properties of IDPs when they are in their free form are their low
hydrophobicity and a relatively high net charge [18]. IDPs possess these properties due to the
specific amino acids that are used to construct their primary structure. IDPs have a biased amino
acid sequence that is skewed towards more disorder-promoting amino acids (Pro, Arg, Gly, Gln,
Ser, Glu, Lys, and Ala) than order-promoting amino acids (Cys, Trp, Tyr, Phe Ile, Leu, Val, and
Asn) [19]. The disorder-promoting amino acids group has more amino acids with net charges at
physiological pH, while the order-promoting amino acids group has more amino acids with
aromatic hydrophobic rings. The balance between these two groups can determine whether the
protein as a whole is ordered or disordered. It is likely that the charges on the protein promote
repulsion and unfolding, while the hydrophobic interactions promote attraction and folding [18].
Having the right combination of these interactions can not only determine whether a protein is
disordered, but also if it remains functional. Although these two interactions are predictable at
physiological conditions, they can be greatly influenced by environmental factors, such as pH,
proteases, and temperature [20].

Environmental factors:
The first environmental factor to be considered is pH, which can both induce further
disorder and help the IDP maintain its physiological structure. Decreasing the pH has been
shown to induce disorder in a human IDP called LL-37, which requires an α-helical
conformation for optimal antibacterial activity. At a pH of 5 the α-helices on LL-37 begin to
degrade, and at a pH of 2 LL-37 becomes entirely disordered. On the contrary, increasing the pH
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to 13 resulted in retention of the α-helical structures of LL-37. It is thought that the unfolding of
α-helices is brought on by protonation of side chains, which increases net charge and therefore
the repulsive force. While increasing folding is driven by reducing repulsive forces due to
neutralization of charged side chains [21].
The next environment factor to consider is proteases. The flexible nature of IDPs makes
them susceptible to degradation from many proteolytic enzymes [19]. Proteases are able to bind
to degradation sites on IDPs because they are unfolded and easily accessible. A common
example of a degradation site on an IDP is a PEST sequence (P = Proline, E = glutamic acid, S =
serine, T = threonine). PEST sequences are characterized as being flexible, unstructured, and
filled with disorder-promoting amino acids. Due to IDPs high sensitivity to proteases, IDPs tend
to have much shorter half-lives than ordered proteins [22].
Finally, it is important to consider temperature, which has been shown to induce
structural changes in IDPs. For example, a change a temperature can alter the stabilization of an
α-helix conformation [23]. It has also been shown that increasing temperature can induce partial
folding in α-Syn. Temperature-induced partial folding is supported by the fact that “the
hydrophobic interaction has the unusual property of increasing in magnitude at higher
temperatures due to the large change in heat capacity with temperature…” [24]. The partial
folding of IDPs from elevated temperature can be reversible by lowering temperatures, which
promotes disorder [20]. In fact, IDPs have been shown to be resilient to many of these
environmental changes.
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Resilience to harsh conditions:
IDPs are highly resilient to harsh conditions because they avoid aggregation, remain
soluble, and can either maintain their function or quickly regain it when conditions normalize.
For example, many IDPs were found to be unaltered after being heated to 90℃. Also, IDPs have
been shown to avoid precipitation after acid treatment, which is attributed to their low
hydrophobicity content. In ordered proteins, hydrophobic residues becoming exposed to solvent
are thought to be a main component to their subsequent aggregation and precipitation. IDP’s
ability to avoid aggregation and precipitation allows them to stay in solution, while typical
ordered proteins do not. If the solution is centrifuged, most of the ordered proteins are found in
the pellet, while the IDPs are isolated in the supernatant. Although the solution is not completely
pure, it still has been useful for researchers to analyze the IDPs that are present [25]. Overall,
environmental factors can induce several structural changes in IDPs, but compared to ordered
proteins, IDPs are highly resilient. It has been suggested that IDPs fit the concept of “one cannot
break what is already broken” [19].
Having a strong understanding of the various environmental factors within the body is
very important when considering the conformation of IDPs, but also for drug design. When
researchers were attempting to stabilize an IDP called DKK2, it was discovered that DKK2’s
conformation was more sensitive to the experimental conditions than the stabilizing molecule
developed [26]. The pH and trehalose concentration were two experimental conditions with
effects on the solubility of DKK2. Reducing the pH had the largest effect on DKK2’s solubility,
with a significant reduction occurring when the pH fell below 9 [26].
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LABORATORY EXPERIMENTS
IDPs susceptibility to
proteolytic degradation by many
different proteases causes them to
have much shorter half-lives than
ordered proteins. Since a decrease

LEGEND
Ratio à Trypsin:TNIP1
PP à Marker proteins
1X à Laemmli buffer control
µg per well à amount of protein in each lane
% acrylamide à determines magnitude of protein shift
Try à Trypsin
Chy à Chymotrypsin

in TNIP1 is associated with disease,
identifying molecules that stabilize its
active form and increase its half-life could
be an important strategy for drug design.
Trypsin and chymotrypsin are two
examples of proteases that can decrease
IDPs’ half-life. Proteases are able to bind
to known degradation sites on IDPs,
which could help identify regions on
TNIP1 to target for drug design. Due to
TNIP1’s susceptibility to proteases, I was
able to learn more about its structure

Gel 1: This gel shows the breakdown of TNIP1
over time at two different trypsin to TNIP1 ratios
at 37℃. Samples were taken at different time
points once the reaction began. When there is
less TNIP1 present, it was gone before the 5minute sample. When TNIP1 was more
abundant, it was still slightly visible at the 15minutes mark.

through a series of experiments. The experiments began by exposing TNIP1 to trypsin and
chymotrypsin at two different temperatures (37℃ and 25℃).
The first step taken was to confirm that trypsin has increased activity at 37℃ compared
to 25℃, and that TNIP1 is broken down faster when the ratio of trypsin to TNIP1 is increased.
These experiments used a purified UBAN fragment of TNIP1 because the fragment has been
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associated with the anti-inflammatory function of TNIP1 [27]. Additionally, using only a
fragment of TNIP1 results in increased clarity. The gels from these experiments are shown as
Gel 1 and 2.
The next step was to purify full length TNIP1 from a nickel column. Although TNIP1 is
difficult to use in size exclusion chromatography, the resulting fractions were pure enough to
proceed with the experiment. These
samples were used to compare the effects
of trypsin and chymotrypsin. This was
done by running both enzymes on one gel
at optimal conditions. The resulting gel
showed that the breakdown of TNIP1 was
Gel 2: This gel was run exactly the same as Gel 1,
but the reactions were carried out at 25℃ instead
of 37℃. Comparing Gel 1 and Gel 2 definitively
shows that trypsin functions more optimally at
37℃ than 25℃. On Gel 1 (37℃), the TNIP1
band (1:1000) dissipates between the 1-minute
and 5-minute samples. On Gel 2 (25℃), the
TNIP1 band (1:1000) dissipates between the 10minute and 15-minute samples. The change in
activity is apparent when comparing the 1:2500
ratios as well.

similar between the two enzymes, but
that trypsin worked faster than
chymotrypsin. To further analyze the
differences between trypsin and
chymotrypsin, comparisons of their
functions were
evaluated at 25℃ and
37℃. Full length
TNIP1 is the
uppermost band and is
clearly broken down

Gel 3: This gel shows the breakdown of TNIP1 at two different
temperatures by trypsin.

over time. While the
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sample is not entirely pure, the approach is still valid because I was simply assessing the changes
to the different bands over a set period of time in the presence of proteases. These gels are
labeled as Gel 3 and Gel 4.
In Gel 3, the band at the bottom of the gel seems to remain unchanged throughout the
duration of the reaction. This could be an ordered region of TNIP1 that does not get recognized
by trypsin. In addition, the band above the 25kD mark also seems relatively unchanged, or even
slightly denser as the reaction occurs. This band could be another ordered region, or potentially a
fragment that accumulates over time. Many results seen in the trypsin gel are similar to the
chymotrypsin gel.
In Gel 4, the band right below the full length TNIP1 becomes the same density as TNIP1
over time. This fragment could potentially be an ordered region, or is simply less likely to be
recognized by chymotrypsin than trypsin. Additionally, a band appears in the 30-minute wells
right above the 50kD
mark. This band is not
present in the trypsin
gel, which suggests
that the band may be
due to fragments
Gel 4: This gel shows the breakdown of TNIP1 at two different
temperatures by chymotrypsin.

accumulating over
time. The difference

in fragments between the two gels is likely due to the differences between trypsin and
chymotrypsin’s ability to recognize cleavage sites within TNIP1.
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Since the recognition sites of trypsin and chymotrypsin are well documented [28],
analyzing the fragments from the gels could provide valuable information about where TNIP1 is
cut and thus disordered. A suspected disordered fragment from one of the gels was cut out and
analyzed by mass spectrometry (MS). The initial assessment of intrinsic disorder in TNIP1 was
done by using a primer for in silico experiments, which were also coupled with in vitro
techniques [29]. This has now been expanded on because the sample from the MS work in
conjunction with further analyses have led to more evidence of TNIP1 being an IDP and an
overall greater depiction of TNIP1’s structure. Specifically, the UBAN domain demonstrated
significant intrinsic disorder when analyzed by nuclear magnetic resonance (NMR). This
provides more evidence that the UBAN domain plays a major role in carrying out the various
functions of TNIP1 [27]. Improving our understanding of TNIP1’s structure is important for
learning more about how it functions as well as for developing small molecule stabilizers that
increase TNIP1’s half-life.
A stabilizer would likely need to protect TNIP1 from degradation by a variety of
proteases. This could lead to TNIP1 performing more of its functions, which could potentially
have benefits in disease states that are associated with decreased TNIP1. However, this is
currently theoretical, so further steps need to be taken to investigate if TNIP1 is even a good
candidate for small molecule binding.

DRUG DESIGN
There are an abundant amount of IDPs in the human body and they play a central role in
psoriasis, cancer, Parkinson’s disease, etc.; thus, learning more about their potential as a drug
target is critical [1]. The cavities of IDPs were examined for druggability and it was found that
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they have a druggable probability of 9%, while ordered proteins only have a druggable
probability of 5%. Druggability was calculated using a proven algorithm from a program called
CAVITY [30]. The algorithm is able to detect whether the geometric shape in a protein’s cavity
is suitable for ligand binding. Since determining druggability in protein cavities requires a known
conformation, it is fair to wonder how IDPs were analyzed using this algorithm. The IDPs were
bound to partner proteins leading to a transition from disordered-to-ordered, which allowed
researchers to identify their conformation when bound. All of the cavities for IDPs were based
purely off of their conformation when they were bound. Although the data shows that IDPs are
promising drug targets, actually discovering effective drugs is difficult because IDPs do not exist
solely in a bound conformation as used in this experiment [30].
In the case of TNIP1, the UBAN fragment has evidence that suggests the presence of two
molecular recognition features called MoRFs. These MoRFs are important for carrying out the
various functions of an IDP because they have the ability to undergo disorder-to-order
transitions. The discovery of potentially two MoRFs in the UBAN fragment of TNIP1 is also
supported by the protease experiments. The results clearly demonstrated that the UBAN
fragment is highly susceptible to degradation by proteases in multiple environments, which
indicates that disorder is present [27]. Identifying MoRFS is a critical step for understanding
function and potential for drug design. Stabilizing MoRFs has been found to acceleration the
association rate constants for transitioning the IDP into the bound state [31]. Therefore, they
could serve as a potential target within an IDP to increase its functionality.
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IDP drug design methods:
Although traditional drug design methods rely on a well-defined structure, there has been
some progress in IDP drug design due to a structure-based virtual screen approach. To carry out
this approach, binding sites of c-Myc had to be identified. Using CAVITY, circular dichroism
(CD), and NMR, c-Myc was inspected for possible binding sites [9]. CD is a quick and effective
method to characterize protein conformational changes and secondary structures. The spectra of
proteins are greatly influenced by its conformation, so CD can be used to monitor
conformational changes due to temperature, denaturants, binding interactions, etc. This makes
CD a valuable tool for characterizing the conformations of IDPs. NMR is also an important asset
to this experiment because it can give residue-specific information, which CD cannot [32].
Together, these tools were able to identify three binding sites on c-Myc. The next step taken was
virtually screening libraries for ligands that have activity in any of the identified binding sites
[9]. A molecular docking methodology called GLIDE uses conformational, orientational, and
positional space to identify ligands that could bind [33]. This method has led to the discovery of
7 molecules that not only bind to the disordered region on c-Myc, but also inhibit its
dimerization. Since overexpression of c-Myc has been associated with a variety of cancers,
preventing its dimerization could pose as a potential therapy for cancer [9]. Developing drugs
that inhibit IDPs is important for proteins that are overexpressed in diseases states like c-Myc.
However, it is also important to research drugs that can increase the activity of IDPs that are
under expressed in disease states, such as TNIP1 for treating psoriasis.
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IDP-stabilizing drug design:
Ligands that can stabilize the active form of an IDP are already being researched. An
example of this is seen when looking into ligands that bind DKK2, an IDP that modulates cancer
and ischemic vascular diseases [26]. It was hypothesized that since DKK2, like many IDPs, are
able to bind RNA-binding proteins (RBPs), then additionally adding an RNA ligand may
contribute to the stabilization of DKK2. This was put to the test and an RBP, LysRS, and an
RNA ligand were able to promote the soluble, stable, and functionally active form of DKK2.
Although the buffer conditions were shown to have a significant effect on the solubility of the
complex, the activity shown in optimal conditions was similar to a known antagonist of the same
pathway. Producing a stabilized and functional form of an IDP by binding the IDP to an RNA
ligand could be a promising method for other IDPs needing stability [26], such as TNIP1.
Another important factor to consider is the effect of RBPs on the regulation of microRNAs
(miR). In fact, 92% of RBP interact directly with at least one miR locus [34]. This is an
important interaction to consider because miR have been shown to alter IDP expression. For
example, miR-27a is a known negative regulator of DKK2 at the translational level [35].
Therefore, RBPs altering miR expression could lead to a downstream effect on an IDP. The
potential clinical effects of the interactions between RBPs, miR, and IDPs should be considered
when using RBPs for IDP stabilization.

Additional IDP drug design factors to consider:
Although IDP drug design seems to be focused on effecting a specific conformation of an
IDP, there have been some thoughts about drugs that bind multiple conformations rather than
just one. The 7 active compounds that inhibited c-Myc dimerization from the virtual screen
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approach all showed multi-conformational-affinity rather than high-conformational-specificity.
Given that all the active compounds demonstrated multi-conformational-affinity, it was
hypothesized that IDPs may prefer to bind multi-conformational-affinity ligands in preference to
high-conformational-specificity ligands. Given the rapid dynamic nature of IDPs, multiconformational-affinity may be described as a ligand cloud binding to a protein cloud [9]. The
ligand and protein cloud concept may be insightful for drug design, but it could spell trouble
from a clinical standpoint because it could lead to unintended effects in other pathways
associated with the IDP.
As previously discussed, the flexibility of IDPs allows for them to have a variety of
functions even within just one pathway, such as TNIP1 and inflammation [1]. One-to-many and
many-to-one binding allows for a range of effects for just one IDP, so drugs that bind IDPs have
the possibility of also exhibiting a range of effects. Inhibiting or stabilizing multiple
conformations could prevent IDPs from fulfilling their functions in pathways not related to the
disease state. In addition, if IDP expression is altered by RBPs or miRs then unintended
consequences could still arise. Unknowingly inhibiting or stimulating pathways could lead to the
IDP-targeting drug being toxic or ineffective.

Drug design methods for IDP stabilizers:
Currently, the drug design methods for stabilizing IDPs have yet to be widely successful.
However, a few methods have led to the identification of small molecule stabilizers for IDPs (see
Table 1). Unfortunately, these current methods are vastly inefficient and the newer strategies
have little evidence to support that they can be easily replicated for other IDPs. Since TNIP1’s
role in disease has become clearer, it is important that we can take the next step by developing
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drugs that can stabilize it. In order to successfully discover lead compounds, the current methods
need to be modified to better suit IDPs. I was able to get a thorough idea of what strategies are
being employed for other IDPs by conducting a comprehensive literature search.
I began the search by compiling a list of terms about the topic. The list was used to find
literature regarding small molecule stabilizers for IDPs and the associated techniques that were
successful. An important part of the process was tracking the combinations of terms I used, so I
could avoid repetitive searches and to evaluate what terms were working the best. After
optimizing the combinations of the search terms, I was able to gather an extensive list of
resources about drug design for IDPs. I included the sources that identified a small molecule that
could stabilize an IDP in Table 1 (next page).
Evidently, there has not been a lot of success in this area. An improved protocol for highthroughput screening (HTS), fragment-based drug design (FBDD), and thermal-shift assays
(TSA) is still highly desired to increase chances of identifying hits. Many computational methods
have been proposed as well to help supplement these current strategies. Finding one universally
applied technique to optimize the benefits from each of these protocols could at least be a step
forward in improving the drug design process. Also, the protocols for identifying small molecule
stabilizers have not been proven to be successful in other IDPs. Therefore, I cannot confidently
say that the current protocols can efficiently identify stabilizers for TNIP1. Since IDPs are
unstructured, may require multi-conformational affinity, and have a low success rate for small
molecule identification, I propose that the solution for IDP and TNIP1 drug design will come in
the form of artificial intelligence (AI).
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Table 1: Summary of Small Molecule Drug Design for IDP
Protein
Stabilized
Foxm

Reference

Technique Used

Advantages and Disadvantages

Bioorg Chem. 2017
Feb;70:12-16. [36]
Diabetes. 2013
Apr;62(4):1297-307.
[38]
Proc Natl Acad Sci
U S A. 2012 Jul
17;109(29):1178893. [39]
Mol Metab. 2018
Mar;9:28-42. [40]

High-throughput
screening (HTS)

αSyn

Sci Rep. 2019 Nov
18;9(1):16947. [41]

14-3-3

J Med Chem. 2020
Jul 9; 63(13): 6694–
6707. [42]

High-throughput
chemical microarray
surface plasmon
resonance imaging
Fragment-based
drug design (FBDD)

Can rapidly screen for activity of
100,000+ compounds daily. Not
small molecule stabilizer specific,
so many false positives. A ligand
binding to an IDP and the
functional outcomes are
especially difficult to detect, so
success rates are as low as 0.04%
[37].
Similar to previous HTS, but is
designed to specifically target
PGC-1a activity from increased
protein stability.
The addition of SPR allows for
improved detection of binding
events

NUPR1

Sci Rep. 2017 Jan
5;7:39732. [44]

PGC-1a
p53

PGC-1a

Cell-based HTS

Thermal-shift assay
(TSA)

Uses smaller starting structures to
identify druggable hotspots,
which can be developed into
small molecules [43]. However, a
major drawback is that most
identified fragments are silent in
assays used for HTS. Therefore,
x-ray crystallography or NMR
studies may need to be used as a
supplement.
Hits were classified as
compounds that increased the
temperature needed for disorder.
The assay is specific to a
stabilizing effect and is a good fit
for small-scale screens. However,
the assay is much less reliable for
proteins with intrinsic disorder
due to non-ideal denaturation
profiles [45].

22
Artificial intelligence in drug design:
AI could help piece together our current strategies to create a synergistic effect.
Researchers have attempted to screen IDPs for small molecule modulators by incorporating AI,
machine learning (ML), and deep learning (DL) into the scientific process. AI can be defined as
“devices that ‘perceive their environment and take actions to maximize their chance of success at
some goal’” [46]. ML and DL are considered subsets of AI. ML is able to learn and improve its
algorithm and therefore its performance over time, while DL “is capable of handling extensive
raw and complex data where it operates by mimicking deep neural networks (DNNs) and
learning processes of the human brain" [47].
AI, ML, and DL are already in use to better understand the complex protein-protein
interaction systems in different disease states. This is illustrated in Figure 1. For instance, ML

Figure 1: This image summarizes the uses of AI in drug discovery [48].
can be used for preparing protein-protein interaction (PPI) libraries and for evaluating druglikeness and ADMET properties of initial PPI hits [47]. For IDPs, DL is already being used to
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identify MoRFs. The DL method only requires the protein sequence for its predictions and is
already outperforming previous models [49]. After MoRF identification, the next step is to
characterize these structural features to help clear up TNIP1’s role in disease. This process is
already underway because ML can provide a convenient framework for analyzing disorder-toorder transitions in IDPs. A ML technique used for carrying out this analysis is called
anharmonic conformational analysis (ANCA), which is able to accomplish this by using fourthorder statistics. This approach has led to the identification of intermediate conformational states
of an IDP called BCL2. These intermediates enable BCL2 to undergo partial unfolding upon
binding to its partner protein BECN1. Also, AI techniques in conjunction with Bayesian
approaches can be used to integrate the experimental and computational simulations to better our
understanding of energetics between IDPs and their respective binding partners. This could
ideally lead to an improved insight into the mechanisms of IDPs [49].
A protocol [37] for efficiently identifying small molecule ligands of disordered proteins
was created and two novel ligands with promising activity for degenerative amyloid disorders
were identified. A key component of this protocol was using ML for identifying and utilizing
chemical characteristics to help focus the screening attempts. One of the ligands is even able to
delay the tau aggregation reaction in vitro. The ligands are chemically different than any other
compound known to affect this process, which indicates that they are interacting with a different
chemical space. Also, these ligands were identified out of just a total of ten compounds that were
characterized in vitro. Given that typical success rates with high-throughput screening are quite
low, this new protocol offers a drastically improved approach. This same approach can easily be
applied to TNIP1 and other IDPs, which makes the protocol enticing for IDP drug design in any
disease state. Although a substantial amount of additional drug development is still required, this
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new method offers a starting point at the minimum [37]. AI evidently can help us learn about
IDP conformations, functions, druggable potential, and even help us find potential active ligands.

Current IDP therapies:
There have been two instances where drugs that target IDPs or IDRs have made clinical
trials. Both were discovered by a phenotypic screen of a natural compound library, which is a
comparable method to cell-based HTS [50,51,52]. The first was Trodusquemine [53], but the
most noteworthy is a drug indicated for prostate cancer called ralaniten, which binds to an IDR
on the androgen receptor [52]. Although the clinical trial only included 28 participants, ralaniten
was well-tolerated and kept several patients stable for over one year. Unfortunately, ralaniten
displayed poor pharmacokinetics (PK), which led to a high pill burden. The next-generation of
ralaniten has improved PK and stability, and is currently recruiting for a phase 1 trial under the
name of EPI-7386 [54]. The lack of IDP-specific drugs currently available should not reflect
IDPs as a limitation for drug development, but instead should represent how IDP drug
development is still very much in the early stages [55]. While ralaniten and its analogs promote
optimism for IDP-targeting drugs in the future, there is still much to be learned about IDPs and
their functions in many disease states. IDPs are highly abundant in the human proteome, so the
potential for IDPs in medicine is untapped. More research in this area could lead to a multitude
of novel mechanisms and FDA-approved drugs.

CONCLUSIONS
•

Discovering drugs that effectively target IDPs could lead to major breakthroughs in
psoriasis, cancer, Parkinson’s disease, ischemic vascular diseases, and beyond.
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•

IDPs use both one-to-many and many-to-one binding mechanisms, which allows them to
have several biological functions in our body. This makes them valuable drug targets in
many different disease states, but this could also increase the chance of side effects if
IDP-targeting drugs make it to the market.

•

Thirty-two percent of the human proteome is IDPs. This makes the use of IDPs in
medicine incredibly underutilized. If researchers are able to refine drug design methods
for IDPs, then there could be a subsequent spike in IDP-targeting drugs moving into
clinical trials.

•

It can be determined if IDPs become ordered after binding to partner proteins using the
Fuzpred algorithm. It could be beneficial to apply this algorithm to IDPs associated with
disease because using an ordered bound structure is a crucial part of drug discovery.
Focusing efforts strictly towards IDPs with ordered conformations after binding could
lead to more clinical trial success.

•

Multi-conformational-affinity may be the approach for current IDP-targeting ligands, but
it is fair to question whether high-conformational-specificity may be used more
frequently in the future. Although IDPs may tend to bind multi-conformational-affinity
over high-conformational affinity, it is justified to believe that multi-conformationalaffinity may lead to more pathways being affected. Whether this leads to a higher
efficacy or more side effects is yet to be determined, so a ligand binding by highconformational-specificity cannot be ruled out.

•

Although IDPs are highly resilient and can maintain their function in harsh conditions,
the environment can still change their conformation which can affect how tightly ligands
bind. Also, IDPs have a short half-life due to their relatively open conformation making
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them highly accessible and thus susceptible to the presence of proteases in the human
body. If a ligand cannot keep up with the production of IDPs then the intended effect will
not be apparent or have a short duration of action. This may be why ralaniten had a high
pill burden.
•

Designing small molecule stabilizers for IDPs has been proven to be challenging. The
current methods each have their own advantages and disadvantages, but a universal
protocol is still in high demand. A potential solution could be AI, which can be used to
piece together the puzzle of IDP drug design.
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